View ValuationEuBiologics 향후 성장Future 기준 점검 0/6현재 EuBiologics 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.핵심 정보n/a이익 성장률n/aEPS 성장률Biotechs 이익 성장24.5%매출 성장률n/a향후 자기자본이익률n/a애널리스트 커버리지None마지막 업데이트n/a최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 27EuBiologics Co., Ltd. (KOSDAQ:A206650) announces an Equity Buyback for KRW 6,000 million worth of its shares.EuBiologics Co., Ltd. (KOSDAQ:A206650) announces a share repurchase program. Under the program, the company will repurchase up to KRW 6,000 million worth of its common stock pursuant to an agreement with NH Investment & Securities. The purpose of the program is stabilization of stock price and enhancement of shareholder value. The program will expire on September 30, 2026. As of March 25, 2026, the company had 0 shares available for acquisition within the dividend-eligible range and 0 shares from other stocks.공시 • Mar 07EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 125, wonmudong-gil, gangwon-do, chuncheon South KoreaValuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩16,200, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 98% over the past three years.New Risk • Feb 04New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩13,820, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 58% over the past three years.Valuation Update With 7 Day Price Move • Nov 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩13,990, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 22% over the past three years.New Risk • Mar 20New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.공시 • Mar 08EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 125, wonmudong-gil, dongsan-myeon, gangwon-do, chuncheon South KoreaNew Risk • Oct 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.분석 기사 • Aug 12Investors Holding Back On EuBiologics Co., Ltd. (KOSDAQ:206650)With a price-to-sales (or "P/S") ratio of 6.1x EuBiologics Co., Ltd. ( KOSDAQ:206650 ) may be sending bullish signals...분석 기사 • May 30Is EuBiologics (KOSDAQ:206650) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Aug 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).공시 • Jul 15Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 TrialPOP Biotechnologies announced top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics. EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO's Spontaneous-nanoliposome antigen particle (SNAP) technology. The phase 3 trial of EuCorVAC-19 was conducted in the Philippines in approximately 2,600 adults (NCT05572879). EuCorVac-18 demonstrated superior antibody immunogenicity compared to a World Health Organization Emergency Use Authorized adenoviral vector vaccine, thereby meeting the primary endpoint of the phase 3 trial. The formation of neutralizing antibodies, which prevent COVID-19 infection, was more than twice as high in EuCorVac- 19 compared to the control vaccine. EuCorVac-20 exhibited a high serological response rate with neutralizing antibody titers increasing after vaccination. In particular, the neutralizing antibody titers and serum response rates in subjects aged over 65 exceeded those of the control vaccine. EuCorVac-19's safety profile was further established in this phase 3 study. EuCorVac-19 showed a slightly lower incidence than the control vaccine of solicited adverse events and there was no difference between EuCorVac-19 and the control vaccine in the incidence of unsolicited adverse events. These results further validate the strength and synergy of POP BIO's SNAP and EuBiologics' EuIMT platform technologies used in the EuCorVac-19 vaccine. Further development of booster vaccines, new strain vaccines, and combination vaccines for COVID-19 will be significantly more straightforward in the future. EuCorVac-19 was already shown to be safe and immunogenic in a Phase I/II clinical trial, the results of which were announced in December 2021. The Philippine Phase 3 trial, conducted since third quarter of 2022, were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the ministry of Health & Welfare, Republic of Korea. Based on the results of this clinical study, EuBiologics plans to apply for product approval in the Philippines shortly. Later this year, results will become available from a second independent Phase 3 clinical study being carried out in the Democratic Republic of Congo.공시 • Feb 04Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South KoreaEuBiologics Co., Ltd. announced on Jan. 28 that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, obtained approval to conduct Phase III comparison clinical trials from the Ministry of Food and Drug Safety in South Korea. Eubiologics is able to commence Phase III comparison trial for 4,000 healthy participants including the Philippines, Bangladesh and other countries based on the standard comparison clinical trial guideline by the Ministry of Food and Drug Safety in Korea. Eubiologics will work closely with the global CROs for recruiting the participants to expedite the entire process in low vaccination rate countries and will also expedite the trial result analysis to advance EuCorVac-19’s regulatory approval and commercialization. Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested. The company has announced Phase I/II trial interim results in December 2021. On the other hand, as EuCorVac-19 has already proved its safety and efficacy through Phase I/II clinical trial, the company expects to expedite the development of Omicron variant vaccine based on the same platform used for EuCorVac-19. Currently, the pre-clinical trial of Mouse immunogenicity test and TG mouse which is transformed from human gene are under progress and the company plans to proceed with the human trial within the 1st half of 2022. In addition, a booster vaccine is necessary due to the dominance of the Omicron variant, and thus the company will commence its trial to prove efficacy as a booster vaccine. Eubiologics has 2 main animal-based bioreactors to produce recombinant protein antigens at Chuncheon Plant 1 and EcML which is adjuvant at Chuncheon Plant 2. The total capacity of COVID-19 vaccine is from 100M to 200M doses per year. EuCorVac-19 vaccine uses the same type of cell line which is for antibody treatment, so if the company uses these facilities, its manufacturing capacity can be further expanded. Eubiologics has already received funds for Phase I/II March 2021 from the new drug development committee of the Ministry of Health and Welfare in Korea and recently submitted the application for phase III trial to get additional financial assistance.Is New 90 Day High Low • Feb 18New 90-day low: ₩17,300The company is down 1.0% from its price of ₩17,450 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 2.0% over the same period.공시 • Feb 10EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.공시 • Jan 22EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in KoreaEuBiologics announced on January 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial. The Phase I trial is designed for 50 healthy adults aged from 19 to 50 years old and will be conducted at ‘the Catholic University of Korea Eunpyeong St. Mary’s Hospital’ evaluating safety, tolerance and immunogenicity. The Phase II trial will be subsequently carried out for 230 adults aged from 19 to 75 years old in four hospitals located in Seoul metropolitan area in order to evaluate dosage and vaccine immunogenicity. EuCorVac-19 under development by EuBiologics is a safe vaccine formulated with the coronavirus spike protein using the recombinant protein technology and with a potent adjuvant, similar to the other virus vaccines already licensed in the world. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. EuBiologics plans to consult with the Korean Ministry of Food and Drug Safety in order to progress the Phase III clinical trial later this year based on the interim results of the Phase I/II trial available no later than June 2021 and receive an emergency use approval of EuCorVac-19, as early as possible. EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing.Is New 90 Day High Low • Jan 04New 90-day high: ₩22,350The company is up 3.0% from its price of ₩21,800 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 18% over the same period.분석 기사 • Dec 08Does EuBiologics (KOSDAQ:206650) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Nov 12New 90-day low: ₩16,000The company is down 9.0% from its price of ₩17,500 on 14 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 26New 90-day low: ₩16,300The company is down 7.0% from its price of ₩17,450 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period.이익 및 매출 성장 예측KOSDAQ:A206650 - 애널리스트 향후 추정치 및 과거 재무 데이터 (KRW Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2025155,00046,000N/AN/A112/31/202496,03524,866N/AN/AN/A12/31/202369,366-13,879-17,20526,452N/A9/30/202359,892-4,361-20,30818,592N/A6/30/202361,222-1,010-29,00411,117N/A3/31/202359,140-1,323-19,7832,854N/A12/31/202255,467-1,099-18,4866,440N/A9/30/202250,4722,022-18,4836,273N/A6/30/202248,5343,808-18,634-688N/A3/31/202242,810-24,462-11,0882,198N/A12/31/202139,385-27,574-16,761-7,602N/A12/31/202028,490-60,134-8,2791,659N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: A206650 의 예상 수익 증가율이 절약률(3.1%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: A206650 의 수익이 KR 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: A206650 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: A206650 의 수익이 KR 시장보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 매출: A206650 의 수익이 연간 20%보다 빠르게 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: A206650의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/11 12:22종가2026/06/11 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스EuBiologics Co., Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hyun Dong SungKB Securities Co., Ltd.Wan KuNH Investment & Securities Co., Ltd.
공시 • Mar 27EuBiologics Co., Ltd. (KOSDAQ:A206650) announces an Equity Buyback for KRW 6,000 million worth of its shares.EuBiologics Co., Ltd. (KOSDAQ:A206650) announces a share repurchase program. Under the program, the company will repurchase up to KRW 6,000 million worth of its common stock pursuant to an agreement with NH Investment & Securities. The purpose of the program is stabilization of stock price and enhancement of shareholder value. The program will expire on September 30, 2026. As of March 25, 2026, the company had 0 shares available for acquisition within the dividend-eligible range and 0 shares from other stocks.
공시 • Mar 07EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 125, wonmudong-gil, gangwon-do, chuncheon South Korea
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩16,200, the stock trades at a trailing P/E ratio of 23.9x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 98% over the past three years.
New Risk • Feb 04New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Feb 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩13,820, the stock trades at a trailing P/E ratio of 20.4x. Average trailing P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 58% over the past three years.
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩13,990, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 22% over the past three years.
New Risk • Mar 20New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. This is currently the only risk that has been identified for the company.
공시 • Mar 08EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025EuBiologics Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 125, wonmudong-gil, dongsan-myeon, gangwon-do, chuncheon South Korea
New Risk • Oct 05New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company.
분석 기사 • Aug 12Investors Holding Back On EuBiologics Co., Ltd. (KOSDAQ:206650)With a price-to-sales (or "P/S") ratio of 6.1x EuBiologics Co., Ltd. ( KOSDAQ:206650 ) may be sending bullish signals...
분석 기사 • May 30Is EuBiologics (KOSDAQ:206650) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Aug 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change).
공시 • Jul 15Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 TrialPOP Biotechnologies announced top line interim results of a Phase 3 clinical trial of EuCorVac-19, a COVID-19 vaccine candidate being developed by South Korean partner EuBiologics. EuCorVac-19 is a protein-based vaccine consisting of a vaccine antigen displayed on immunogenic nanoparticles, using POP BIO's Spontaneous-nanoliposome antigen particle (SNAP) technology. The phase 3 trial of EuCorVAC-19 was conducted in the Philippines in approximately 2,600 adults (NCT05572879). EuCorVac-18 demonstrated superior antibody immunogenicity compared to a World Health Organization Emergency Use Authorized adenoviral vector vaccine, thereby meeting the primary endpoint of the phase 3 trial. The formation of neutralizing antibodies, which prevent COVID-19 infection, was more than twice as high in EuCorVac- 19 compared to the control vaccine. EuCorVac-20 exhibited a high serological response rate with neutralizing antibody titers increasing after vaccination. In particular, the neutralizing antibody titers and serum response rates in subjects aged over 65 exceeded those of the control vaccine. EuCorVac-19's safety profile was further established in this phase 3 study. EuCorVac-19 showed a slightly lower incidence than the control vaccine of solicited adverse events and there was no difference between EuCorVac-19 and the control vaccine in the incidence of unsolicited adverse events. These results further validate the strength and synergy of POP BIO's SNAP and EuBiologics' EuIMT platform technologies used in the EuCorVac-19 vaccine. Further development of booster vaccines, new strain vaccines, and combination vaccines for COVID-19 will be significantly more straightforward in the future. EuCorVac-19 was already shown to be safe and immunogenic in a Phase I/II clinical trial, the results of which were announced in December 2021. The Philippine Phase 3 trial, conducted since third quarter of 2022, were supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the ministry of Health & Welfare, Republic of Korea. Based on the results of this clinical study, EuBiologics plans to apply for product approval in the Philippines shortly. Later this year, results will become available from a second independent Phase 3 clinical study being carried out in the Democratic Republic of Congo.
공시 • Feb 04Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South KoreaEuBiologics Co., Ltd. announced on Jan. 28 that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, obtained approval to conduct Phase III comparison clinical trials from the Ministry of Food and Drug Safety in South Korea. Eubiologics is able to commence Phase III comparison trial for 4,000 healthy participants including the Philippines, Bangladesh and other countries based on the standard comparison clinical trial guideline by the Ministry of Food and Drug Safety in Korea. Eubiologics will work closely with the global CROs for recruiting the participants to expedite the entire process in low vaccination rate countries and will also expedite the trial result analysis to advance EuCorVac-19’s regulatory approval and commercialization. Eubiologics is developing EuCorVac-19, its vaccine platform, which consists of owned antigen, EulMT in-licensed from Korea Institute of Science and Technology and SNAP technology of POP Biotechnologies that EuBiologics has invested. The company has announced Phase I/II trial interim results in December 2021. On the other hand, as EuCorVac-19 has already proved its safety and efficacy through Phase I/II clinical trial, the company expects to expedite the development of Omicron variant vaccine based on the same platform used for EuCorVac-19. Currently, the pre-clinical trial of Mouse immunogenicity test and TG mouse which is transformed from human gene are under progress and the company plans to proceed with the human trial within the 1st half of 2022. In addition, a booster vaccine is necessary due to the dominance of the Omicron variant, and thus the company will commence its trial to prove efficacy as a booster vaccine. Eubiologics has 2 main animal-based bioreactors to produce recombinant protein antigens at Chuncheon Plant 1 and EcML which is adjuvant at Chuncheon Plant 2. The total capacity of COVID-19 vaccine is from 100M to 200M doses per year. EuCorVac-19 vaccine uses the same type of cell line which is for antibody treatment, so if the company uses these facilities, its manufacturing capacity can be further expanded. Eubiologics has already received funds for Phase I/II March 2021 from the new drug development committee of the Ministry of Health and Welfare in Korea and recently submitted the application for phase III trial to get additional financial assistance.
Is New 90 Day High Low • Feb 18New 90-day low: ₩17,300The company is down 1.0% from its price of ₩17,450 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 2.0% over the same period.
공시 • Feb 10EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021EuBiologics Co., Ltd., Annual General Meeting, Mar 25, 2021, at 10:00 Korea Standard Time.
공시 • Jan 22EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in KoreaEuBiologics announced on January 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial. The Phase I trial is designed for 50 healthy adults aged from 19 to 50 years old and will be conducted at ‘the Catholic University of Korea Eunpyeong St. Mary’s Hospital’ evaluating safety, tolerance and immunogenicity. The Phase II trial will be subsequently carried out for 230 adults aged from 19 to 75 years old in four hospitals located in Seoul metropolitan area in order to evaluate dosage and vaccine immunogenicity. EuCorVac-19 under development by EuBiologics is a safe vaccine formulated with the coronavirus spike protein using the recombinant protein technology and with a potent adjuvant, similar to the other virus vaccines already licensed in the world. EuCorVac-19 is a liquid injection in glass vials and can be stored and distributed at refrigerated temperatures which can take advantage of the general distribution system for biopharmaceuticals. EuBiologics plans to consult with the Korean Ministry of Food and Drug Safety in order to progress the Phase III clinical trial later this year based on the interim results of the Phase I/II trial available no later than June 2021 and receive an emergency use approval of EuCorVac-19, as early as possible. EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing.
Is New 90 Day High Low • Jan 04New 90-day high: ₩22,350The company is up 3.0% from its price of ₩21,800 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 18% over the same period.
분석 기사 • Dec 08Does EuBiologics (KOSDAQ:206650) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Nov 12New 90-day low: ₩16,000The company is down 9.0% from its price of ₩17,500 on 14 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 26New 90-day low: ₩16,300The company is down 7.0% from its price of ₩17,450 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 12% over the same period.